Incorporating a Patient Dichotomous Characteristic in Cancer Phase I Clinical Trials Using Escalation with Overdose Control

Table 5

EWOC. Design operating characteristic with respect to safety and efficiency of the trial.

𝛾	0.2	0.4	0.6	0.8
Proportion of DLTs	0.3372	0.2778	0.2162	0.1737
Proportion overdosed	0.3684	0.2067	0.0417	0.0001
Bias (𝛾)	−0.0086	−0.0249	−0.08124	−0.1915
MSE (𝛾)	0.0464	0.0858	0.1381	0.2246